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Abstract
Background/Aim. Vitamin D deficiency is a well-establi-
shed risk factor for bone disease, but emerging data suggest
that altered vitamin D homeostasis may play a role in the de-
velopment of type 2 diabetes mellitus (T2DM), dyslipidemia
hypertension, and other cardiovascular diseases (CVD). The
aim of this study was to investigate the prevalence of vitamin
D deficiency in patients with T2DM with/without CVD, to
correlate it with anthropometric and metabolic parameters
and to determine the predictors of vitamin D deficiency.
Methods. A total of 88 patients with T2DM (49 male/39
female, aged 61.0 ± 0.9 yrs, body mass index (BMI) 29.9 ±
0.4 kg/m2) and 67 patients (44 male/23 female, aged 63.6 ±
1.0 yrs, BMI 29.2 ± 0.5 kg/m2) with T2DM and CVD (myo-
cardial infarction in 57 patients and angina pectoris in 10 pa-
tients) were included in this study. These patients were com-
pared with 87 healthy subjects (35 male/52 female, aged 52.8
± 1.4 yrs, BMI 27.2 ± 0.5 kg/m2). Weight, height, waist cir-
cumference and BMI were recorded in all patients. Also, to-
tal cholesterol, triglycerides, hemoglobin A1c (HbA1c) and
25-hydroxy-vitamin D [25(OH)D] levels were measured in
all. According to 25(OH)D level, all subjects were divided
into three categories: severe vitamin D deficiency ( 15
ng/mL), vitamin D insufficiency (15–20 ng/mL) and vita-
min D sufficiency (  20 ng/mL). We correlated vitamin D
levels with anthropometric and metabolic status and deter-
mined the predictors of vitamin D deficiency. Results. Se-
vere vitamin D deficiency was registered in 16.1% healthy
subjects, in 21.6% patients with T2DM and in 26.9% pa-
tients with T2DM and CVD. Patients with T2DM who were
vitamin D deficient had increased weight, waist circumfer-
ence, cholesterol and triglyceride levels when compared with
patients with T2DM who had sufficient vitamin D level.
25(OH)D levels correlated with BMI and waist circumfer-
ence in all subjects, but did not correlate with metabolic pa-
rameters (lipids, HbA1c). The best predictors of vitamin D
level in all subjects were weight, waist circumference and
BMI. Conclusion. The high prevalence of vitamin D defi-
ciency in patients with T2DM and particularly in patients
with T2DM and CVD suggests that supplementation with
vitamin D may be beneficial although there is still not suffi-
cient evidence for recommending prescribing vitamin D.
Key words:
diabetes mellitus, type 2; cardiovascular disease;
vitamin d deficiency; body weight; body mass index;
risk factors.
Apstrakt
Uvod/Cilj. Nedostatak vitamina D je poznat faktor rizika
od oboljenja skeleta. Sve je više podataka o ulozi nedostatka
vitamina D u razvoju dijabetesa melitusa tipa 2 (T2DM), di-
slipidemije, hipertenzije, i drugih kardiovaskularnih bolesti
(KVB). Cilj studije bio je da se ustanovi uÿestalost nedostat-
ka vitamina D kod bolesnika sa T2DM sa ili bez KVB, ko-
relacija nedostatka vitamina D sa antropometrijskim i meta-
boliÿkim parametrima i odrede prediktori nedostatka vita-
mina D. Metode. U studiju je bilo ukljuÿeno 88 bolesnika
sa T2DM [(49 muškaraca/39 žena, životno doba 61,0 ± 0,9
god, indeks telesne mase (ITM) 29,9 ± 0,4 kg/m2)] i 67 bo-
lesnika (44 muškaraca/23 žena, životno doba 63,6 ± 1,0
god, ITM 29,2 ± 0,5 kg/m2) sa T2DM i KVB (infarkt mio-
karda kod 57 bolesnika i angina pektoris kod 10 bolesnika).
Ovi bolesnici su uporeĀeni sa 87 zdrava ispitanika (35 muš-
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0,5 kg/m2). Mereni su telesna masa, visina, obim struka i
ITM, kao i nivo holesterola, triglicerida, hemoglobina A1c
(HbA1c) i 25-hidroksi vitamin D[25(OH)D]. Prema nivou
25(OH)D svi ispitanici bili su podeljeni u tri grupe: težak
nedostatak vitamina D ( 15 ng/mL), nedostatak vitamina
D (15–20 ng/mL) i zadovoljavajuýi nivo vitamina D (  20
ng/mL). Ispitana je korelacija nivoa vitamina D sa antro-
pometrijskim i metaboliÿkim parametrima i odreĀeni su
prediktori nedostatka vitamina D. Rezultati. Težak nedos-
tatak vitamina D registrovan je kod 16,1% zdravih ispitani-
ka, 21,6% bolesnika sa T2DM i 26,9% bolesnika sa T2DM i
KVB. Bolesnici sa T2DM koji su imali težak nedostatak vi-
tamina D imali su veýu telesnu masu, obim struka, nivoe
holesterola i triglicerida u poreĀenju sa bolesnicima sa
T2DM koji su imali zadovoljavajuýi nivo vitamina D. Nivo
25(OH)D korelisao je sa ITM i obimom struka kod svih is-
pitanika, ali nije korelisao sa metaboliÿkim parametrima (li-
pidi, HbA1c).  Najbolji prediktori nivoa vitamina D kod svih
ispitanika bili su telesna masa, obim struka i ITM. Zaklju-
ÿak. Visoka uÿestalost nedostatka vitamina D kod bolesnika
sa T2DM, a posebno kod bolesnika sa T2DM i KVB uka-
zuje na potrebu supstitucije vitaminom D iako još uvek ne-
ma dovoljno podataka o tome.
Kljuÿne reÿi:
dijabetes melitus, insulin-nezavisni; kardiovaskularne
bolesti; vitamin d, nedostatak; telesna težina; telesna
masa, indeks; faktori rizika.
Introduction
Vitamin D is crucial not only to maintain bone strength,
but research also suggests it plays a role in immune system
functioning, cancer prevention, glucose and lipid metabolism
and cardiovascular health
 1. Just recently Task Force of the
Endocrine Society released guidelines to clinicians for the
evaluation, treatment and prevention of vitamin D deficiency
with an emphasis on the care of patients who are at risk for
deficiency
 2. Considering that vitamin D deficiency is very
common in all age groups and that few foods contain vitamin
D, Task Force recommended supplementation depending on
age and clinical circumstances.
Vitamin D is formed mainly in the skin by photolysis of
steroid precursors by ultraviolet B radiation and is also found
in fish, eggs, fortified milk, cod liver oil, and supplements.
Newly formed vitamin D is bound to vitamin D binding
protein (DBP) and transported to the liver where is hy-
droxylated to 25-hydroxyvitamin D [(25(OH)D)]. 25(OH)D
is further hydroxylated in the kidney to 1,25-dihydroxy-
vitamin D [(25(OH)2D)], the most active metabolite of vita-
min D
 3. However, serum 25(OH)D is regarded as the best
indicator of vitamin D status in individuals without kidney
disease, because it is the substrate for the renal and nonrenal
production of 1,25(OH)2D, has a longer biological half-life
than 1,25(OH)2D and circulates in much higher concentra-
tions. Serum 25(OH)D reflects the total production of vita-
min D from both endogenous and exogenous sources, in-
cluding exposure to ultraviolet-B radiation and intake of
various dietary forms. People who are at high risk for vita-
min D deficiency are the elderly, dark skinned, obese, those
who cover all exposed skin or use sunscreen, patients with
fat malabsorption syndromes or inflammatory bowel dis-
ease
 4–7.
At present, there is no consensus on the optimal level
of vitamin D; however, it has been suggested that serum
25(OH)D levels greater than 25 ng/mL (Endocrine Society
Guidelines 30 ng/mL) are required for optimal health and
that values less than 15 ng/mL (Endocrine Society Guide-
lines 20 ng/mL) have been associated with decreases in
bone density and other negative effects of vitamin D defi-
ciency
 2, 8.
Recently, many studies have reported an inverse asso-
ciations between serum 25(OH)D levels and the risk of a va-
riety of diseases, including diabetes mellitus (DM), cardio-
vascular disease (CVD), cancer, autoimmune diseases, in-
fections, or cognitive decline
 9 . Clinically, vitamin D has
been shown to be linked with glucose and insulin homeosta-
sis.  Observational studies show a relatively consistent asso-
ciation between low vitamin D status and DM, both type 1
DM and type 2 (T2DM) or metabolic syndrome 
10–12. It’s al-
ready well-known that children living in areas of the world
without much sunlight, such as Finland, have higher rates of
type 1 diabetes than those in sunnier parts of the world. In
fact, infants in Finland are 400 times more likely to develop
DM than infants in Venezuela 
13. Some research indicates
that infants and children given vitamin D supplements are
less likely to develop type 1 DM. Many studies have shown
that supplementing with vitamin D and calcium slows the
progression to T2DM. Vitamin D deficiency is commonly
found in people with poor DM control. As the deficiency
worsened, so did DM control. A minority of DM patients
took vitamin D supplements. The molecular mechanisms of
association of vitamin D deficiency with DM, hypertension,
obesity and CVD remain incompletely understood.
As low vitamin D status has been suggested  to be a risk
factor for T2DM and for CVD, the aim of this study was to
determine vitamin D levels  in patients with T2DM and in
patients with T2DM and CVD and correlate the levels of vi-
tamin D to their anthropometric and metabolic status.
Methods
A total of 88 patients with T2DM [49 male and 39 fe-
male, aged 61.0 ± 0.9 yrs, body mass index (BMI) 29.9 ± 0.4
kg/m
2] and 67 patients (44 male and 23 female, aged 63.6 ±
1.0 yrs, BMI 29.2 ± 0.5 kg/m
2) with history of both T2DM
and CVD (myocardial infarction in 57 patients and angina
pectoris in 10 patients were included in this study). These
patients were compared with 87 healthy subjects (35 male
and 52 female, aged 52.8 ± 1.4 yrs, BMI 27.2 ± 0.5 kg/m
2)
with no history of DM or CVD.
Informed consent for the study was obtained from all
patients and from healthy subjects. The protocol was ap-Volumen 70, Broj 2 VOJNOSANITETSKI PREGLED Strana 165
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proved by the Ethical Committee of University Clinical
Center Podgorica.
The patients' age, weight, height, waist circumference
and calculated BMI were recorded. Serum samples were ob-
tained in the morning after an overnight fast. In serum sam-
ples we measured total cholesterol, triglycerides, hemoglobin
A1c (HbA1c) and 25(OH)D levels. HbA1c was measured with
immunoturbimetric analysis (COBAS INTEGRA), choles-
terol was measured with enzymatic methodology, while tri-
glycerides were measured with glycerol phosphate oxidase
methodology. The HbA1c provides an average measurement
of blood sugar control over about a 12-week span. For peo-
ple with DM, the goal is 7%, for healthy people, the normal
range is 4%–6%. Serum levels of 25(OH)D were measured
by commercial enzyme immunotest (EIA, Immunodiagnostic
system, UK). The limit of detection for 25(OH)D was 5
ng/mL.
Parameters of descriptive statistics are presented as
mean r standard error (SE). For statistical analysis we used
parametric  t-test, nonparametric Mann-Whitney test and
ANOVA. We analyzed the influence of sex, age, weight,
waist circumference and BMI on vitamin D level. We ana-
lyzed the correlation between anthropometric and metabolic
parameters and vitamin D level using Spearman's correla-
tion. We used the multiple regression analysis for determi-
nation of predictors of vitamin D level. Statistical analysis
was performed with SPSS for Windows (version 15.0). P
value < 0.05 was considered as statistically significant.
Results
Clinical characteristics of three groups of participants in
the study (patients with T2DM, patients with T2DM and
CVD, and healthy subjects, are presented in Table 1.
HbA1c and lipid levels in patients with T2DM and pa-
tients with T2DM and CVD are presented in Table 2. Pa-
tients with T2DM had higher levels of HbA1c and cholesterol
compared with patients with T2DM and CVD (p < 0.01).
Vitamin D levels in patients and healthy subjects are
shown in Table 3.
There were no differences in 25(OH)D levels between
male and female subjects in all investigated groups (data not
shown). There was no difference in vitamin D levels between
patients with hypertension (51.0 ± 1.8 ng/mL) and with nor-
mal blood pressure (54.1 ± 1.6 ng/mL; p > 0.05).
Table 2
Hemoglobin A1c (HbA1c), cholesterol and triglyceride levels
in the patients with type 2 diabetes mellitus (T2DM) and the
patients with T2DM and cardiovascular disease (CVD)
Parameters T2DM T2DM and CVD
HbA1c (%) 7.6* 7.2
Cholesterol (mmol/L) 6.1* 5.5
Triglycerides (mmol/L) 2.8 2.3
*p < 0.01 vs T2DM and CVD
Table 3
25-hydroxyvitamin D [25(OH)D] level in the patients with
type 2 diabetes (T2DM), the patients with T2DM and
cardiovascular disease (CVD) and in the healthy subjects
Groups of patients 25(OH)D (ng/mL)
T2DM 21.7 ± 0.8 (6.8–44.8)
T2DM and CVD 19.4 ± 0.8* (7.6–33.2)
Healthy subjects 22.6 ± 0.8 (8.0–55.2)
*SE – standard error; p < 0.01 vs healthy subjects
In all subjects, 25(OH)D levels inversely correlated
with BMI (r = -0.127, p = 0.048) and waist circumference (r
= -0.165, p = 0.010), but did not correlate with metabolic pa-
rameters (lipids, HbA1c). According to 25(OH)D level, we
divided all subjects into three categories: severe vitamin D
deficiency (less than 15 ng/mL), vitamin D insufficiency (15
to 20 ng/mL) and vitamin D sufficiency (above 20 ng/mL).
Table 4 shows the vitamin D status in all studied patients.
The percentages of patients with severe vitamin D deficiency
and vitamin D insufficiency were the highest (26.9% both) in
patients with T2DM and CVD.
Nineteen patients with T2DM (21.6%) were severe vi-
tamin D deficient. Clinical characteristics of these patients
are presented in Table 5. Patients with T2DM who were vi-
tamin D deficient had increased body weight and waist cir-
cumference  (p < 0.05) compared with patients with T2DM
and vitamin D > 20 ng/mL. Cholesterol and triglyceride lev-
Table 1
Clinical characteristics of the patients with type 2 diabetes mellitus (T2DM), the patients with T2DM
and cardiovascular disease (CVD) and in the healthy subjects
Characteristics T2DM patients
 (n = 88)
T2DM and CVD
patients (n = 67)
Healthy subjects
(n = 87)
Sex (male/female), n 49/39 44/23 35/52
Age (years), ʉ ± SE 61.0 ± 0.9 63.6 ± 1.0 52.8 ± 1.4
Duration of diabetes mellitus (years), ʉ ± SE 7.6 ± 0.6 10.2 ± 0.8 –
Hypertension (yes/no), n 40/48 49/18 –
Weight (kg), ʉ ± SE 88.2 ± 1.6* 85.5 ± 2.0 81.8 ± 1.5
Height (cm), ʉ ± SE 172.6 ± 1.0 171.8 ± 1.2 173.6 ± 1.1
BMI (kg/m
2), ʉ ± SE 29.9 ± 0.4* 29.2 ± 0.5* 27.2 ± 0.5
Waist (cm), ʉ ± SE 99.5 ± 1.2* 99.7 ± 1.4* 91.5 ± 1.5
Therapy
insulin 45 35 –
OAD 43 32 –
*p < 0.01 vs healthy subjects; SE – standard error; BMI – body mass index; OAD – oral antidiabeticsStrana 166 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
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els were higher in patients with severe vitamin D deficiency
compared to those with vitamin D 15–20 ng/mL and > 20
ng/mL (p < 0.01; Table 6).
Eighteen patients with T2DM and CVD (26.9%) had
severe vitamin D deficiency and the same number of patients
had vitamin D insufficiency. Clinical characteristics of these
patients are presented in Table 7. There were no differences
in various parameters (anthropometric, lipids, or HbA1c)
between three subgroups of patients divided according to vi-
tamin D status (severe vitamin D deficiency, vitamin D in-
sufficiency and vitamin D sufficiency, Table 8).
Table 4
Percentage of subjects with severe vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency in the patients
with type 2 diabetes mellitus (T2DM), patients with T2DM and cardiovascular disease (CVD) and in healthy subjects
25(OH)D
(ng/mL)
Vitamin D status T2DM patients
(%)
T2DM and CVD
patients (%)
Healthy subjects
(%)
< 15 severe deficiency 21.6 26.9 16.1
15–20 insufficiency 18.2 26.9 14.9
> 20 sufficiency 60.2 46.2 69
25(OH)D – 25-hydroxyvitamin D
Table 5
Clinical characteristics of 88 patients with type 2 diabetes mellitus (T2DM) divided in 3 categories according to
vitamin D status (severe vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency)
25(OH)D in patients with T2DM Variables  15 15–20 > 20
Number (%) 19 (21.6) 16 (18.2) 53 (60.2)
Age (years), ± SE 59.7 ± 1.9 62.4 ± 2.1 61.0 ± 1.3
Weight (kg), ± SE 88.8 ± 4.0* 85.9 ± 4.0 88.7 ± 1.9
Height (cm), ± SE 169.4 ± 2.5 169.3 ± 2.3 174.8 ± 1.3
BMI (kg/m
2), ± SE 31.0 ± 1.0 30.4 ± 1.1 29.4 ± 0.5
Waist (cm), ± SE 103.8 ± 2.6* 99.4 ± 3.2 97.9 ± 1.3
*p < 0.05 vs 20 ng/mL; BMI – body mass index; [25(OH)D] – 25-hydroxyvitamin D
Table 6
Hemoglobin A1c (HbA1c), cholesterol and triglyceride levels in the patients with type 2 diabetes (T2DM) divided in 3
categories according to vitamin D status (severe vitamin D deficiency, vitamin D insufficiency and vitamin D
sufficiency)
25(OH)D
(ng/mL)
Vitamin D status HbA1c
(%)
Cholesterol
(mmol/L)
Triglycerides
(mmol/L)
< 15* severe deficiency 7.7 6.8* 4.7*
15–20* insufficiency 7.4 5.7 2.3
> 20* sufficiency 7.6 5.9 2.3
*p < 0.05 vs group with 15–20 ng/mL and 20 ng/mL 25(OH)D
Table 7
Clinical characteristics of 67 patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD) divided in 3 categories
according to vitamin D status (severe vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency)
Vitamin D status measured by 25-hydroxyvitamin D level in patients with T2DM and CVD Variables  15 ng/mL 15–20 ng/mL > 20 ng/mL
Number of patients
(%)
18 (26.9) 18 (26.9) 31 (46.2)
Age (years), ± SE 63.7 ± 1.7 64.1 ± 2.4 63.2 ± 1.5
Weight (kg), ± SE 87.1 ± 5.1 85.0 ± 4.6 84.9 ± 1.9
Height (cm), ± SE 169.5 ± 2.1 173.7 ± 3.0 172.1 ± 1.6
BMI (kg/m
2), ± SE 30.2 ± 1.2 28.3 ± 0.9 29.3 ± 0.6
Waist (cm), ± SE 102.7 ± 3.2 98.6 ± 2.6 98.5 ± 1.7
Table 8
Hemoglobin A1c (HbA1c), cholesterol and triglyceride levels in the patients with type 2 diabetes (T2DM) and
cardiovascular disease (CVD) divided in 3 categories according to vitamin D status (severe vitamin D deficiency,
vitamin D insufficiency and vitamin D sufficiency)
25(OH)D
(ng/mL)
Vitamin D status HbA1c
(%)
Cholesterol
(mmol/L)
Triglycerides
(mmol/L)
< 15* severe deficiency 7.3 5.3 2.4
15–20* insufficiency 7 5.4 2.3
> 20* sufficiency 7.2 5.6 2.2Volumen 70, Broj 2 VOJNOSANITETSKI PREGLED Strana 167
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The best predictors of 25(OH)D levels in all subjects
were weight (p = 0.0001), waist circumference (p = 0.006)
and BMI (p = 0.001). In patients with T2DM predictors of
25(OH)D levels were weight (p = 0.0001) and waist circum-
ference (p = 0.004). In patients with T2DM and CVD the
best predictor of 25(OH)D  level was BMI (p = 0.006).
Discussion
According to our results, a substantial percentage of pa-
tients with T2DM, patients with T2DM and CVD, as well as
healthy subjects were vitamin D deficient. The worst situation
was in the group of patients with T2DM and CVD in which
27% were vitamin D deficient. We found a negative correla-
tion between serum vitamin D levels and BMI and waist cir-
cumference in our patients, which is in accordance with other
studies
 4, 7. We did not find any gender differences in serum
vitamin D levels, in contrast to other studies in which the
authors reported higher levels in men than in women
 5, 6. We
did not find any correlation between serum vitamin D levels
and age or metabolic parameters (HbA1c, lipids).
The strongest relationship (inverse) was found between
25(OH)D levels and BMI and waist circumference. The
negative relationship between 25(OH)D and fat mass has
been attributed to increased sequestration of fat-soluble vi-
tamin D in adipocytes. It is hypothesized that vitamin D gen-
erated in the skin or orally ingested  is sequestered into adi-
pocytes before it is transported to the liver and converted to
25(OH)D
 14. It is not known whether the adipocytes simply
store vitamin D or actively catabolize it. Other study showed
that changes in 25(OH)D levels with age, gender, or fat mass
are not due to genetic variability of vitamin D binding pro-
tein
 15. Consistently observed negative relationships of
25(OH)D with body composition have a biological origin
other than adaptation to plasma transport. Thus obese people
are at risk for vitamin D deficiency and may need 2–3 times
more vitamin D for their age group to satisfy their bodies
vitamin D requirement
 2.
Vitamin D deficiency is highly prevalent worldwide
and essentially everyone is at risk
 2. Low levels of 25(OH)D
are present in as many as one third to one half of otherwise
healthy middle-aged to elderly adults
 1, 16, 17. Limited cutane-
ous synthesis due to inadequate sun exposure or pigmented
skin and inadequate dietary intake are the principal causes of
low 25(OH)D levels. Although the best characterized conse-
quences of vitamin D deficiency involve the musculoskeletal
system, a growing body of evidence suggests that low levels
of vitamin D may negatively affect the glucose and insulin
homeostasis and the cardiovascular system as well, leading
to hyperglycemia, insulin resistance, hypertension, heart dis-
ease and cognitive decline in the elderly population
 18, 19. Ob-
servational studies showed the association between vitamin
D levels deficiency and impaired glucose tolerance or
T2DM
 10, 11, 20–22. Glycemic control in T2DM depends on the
season, with the lowest HbA1c levels during summer
 23. Data
from the Nurses’ Health Study found that women who took a
combination of 1,200 mg of calcium and more than 800 IU
of vitamin D daily had a 33% lower chance of getting T2DM
than women taking smaller amounts of these nutrients
 10. It
seems that subjects with vitamin D deficiency are at higher
risk of insulin resistance and the metabolic syndrome. The
unredlying  mechanism could be an effect of vitamin D on
insulin sensitivity, on ȕ-cell function, or on both
 11. The pan-
creatic ȕ-cells express vitamin D receptor
 24. Vitamin D defi-
ciency inhibits insulin secretion and modulates lipolysis
 25.
Vitamin D supplementation improves insulin secretion, in-
sulin sensitivity and glucose tolerance in vitamin D-deficient
animals and in humans
 26–28. Treatment with vitamin D3 in
patients with T2DM increased plasma 25(OH)D and the first
phase of the insulin secretion evaluated by an intravenous
glucose tolerance test
 28.
Cardiovascular system is also affected by vitamin D de-
ficiency. Vitamin D deficiency has been observed in patients
with acute myocardial infarction, stroke and heart failure and
CVD
 29–32. Data from the Framingham Heart Study indicate
that patients with the lowest levels of vitamin D were 62%
more likely to have either a heart attack or a stroke than
those with higher vitamin D levels. The results were so im-
pressive that authors believe that people should take between
1,000 and 2,000 IU of vitamin D every day. Patients with
heart failure have lower plasma levels of 25(OH)D and
1,25(OH)2D than controls
 31,  33. Another large prospective
study of Wang et al. 
34 in more than 1,700 subjects showed
that vitamin D deficiency is associated with increased car-
diovascular risk
 34. The authors showed that the higher risk
(2-fold risk) was evident among subjects with hypertension,
in whom 25(OH)D levels were bellow 15 ng/mL. With this
cut point, the prevalence of vitamin D deficiency in the study
of Wang et al. 
34 was 28%, similar to our results and results
reported in other large epidemiological studies 
35.
In the UK an increased cardiovascular morbidity was
associated with low plasma 25(OH)D concentrations in
winter. Similarly, blood pressure was higher in winter than in
summer, varies with skin pigmentation and is higher in sub-
jects with vitamin D deficiency
 36, 37. Vitamin D receptors are
identified in many tissues, including vascular smooth mus-
cle, endothelium and cardiomyocytes
 1, 38.  In vitro,
1,25(OH)2D suppresses renin gene expression, regulates the
growth and proliferation of vascular smooth muscle cells and
cardiomyocytes
 39, 40. In knockout mice model, the absence of
vitamin D receptor activation results with the upregulation of
the renin-angiotensin system, hypertension and left ven-
tricular hypertrophy
 27, 41. Vascular smooth muscle cells and
endothelial cells have the ability to convert circulating
25(OH)D to 1,25(OH)2D
 42. Furthermore, atherosclerosis
may be viewed as a chronic inflammatory disease that in-
volves several cytokines (TNF-Į, IL-6). Active vitamin D
can suppress these cytokines in vivo and TNF-Į is inversely
related to plasma 25(OH)D in vivo
 43.
Management of vitamin D deficiency may be a simple
and cost-effective method to improve blood sugar control,
arterial hypertension, dyslipidemia, atherosclerosis and pre-
vent the serious complications associated with these patho-
logical conditions. Diet alone may not be sufficient to man-
age vitamin D levels.  Based on our and other studies people
at risk for DM, dyslipidemia and CVD should be screenedStrana 168 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
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for low vitamin D levels which allow health care profession-
als to identify a nutrient deficiency early on. Getting
25(OH)D consistently above 30 ng/mL  may requier 1000–
2,000 IU/day of vitamin D as suggested by the recent Endo-
crine Society Guideline 
2.
Conclusion
The results of the present study suggest that vitamin D
deficiency is highly prevalent in patients with T2DM and
particularly in patients with T2DM and CVD. The best pre-
dictors of vitamin D status seem to be weight, BMI and waist
circumference all related to the metabolic status. There is no
sufficient evidence yet to recommend prescribing vitamin D
to attain the benefit for cardiovascular protection, however
interventional studies are awaited.
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